Clinical trial
CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00016328 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00016328 |
|---|---|
| Title | CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme |
| Official title | A Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor |
| Intervention type | Drug, Other |
| Interventions | temsirolimus, laboratory biomarker analysis, pharmacological study |
| Enrollment | 33 |
| Start date | May 1, 2001 |
| Primary completion | Aug 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: